July 30, 2016 6:52 PM ET

Pharmaceuticals

Company Overview of Aerpio Therapeutics, Inc.

Company Overview

Aerpio Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development of novel therapeutics for vascular disorders. It offers therapeutics for the treatment of diabetic macular edema and inflammatory bowel diseases. The company was incorporated in 2011 and is based in Cincinnati, Ohio.

9987 Carver Road

Suite 420

Cincinnati, OH 45242

United States

Founded in 2011

Phone:

513-985-1920

Fax:

513-985-0999

Key Executives for Aerpio Therapeutics, Inc.

Chief Executive Officer, President and Director
Chief Medical Officer
Vice President of Medical Affairs
Vice President of Clinical Science
Chief Scientific Officer
Compensation as of Fiscal Year 2016.

Aerpio Therapeutics, Inc. Key Developments

Aerpio Therapeutics, Inc. Presents at 15th Annual Needham Healthcare Conference, Apr-12-2016 10:00 AM

Aerpio Therapeutics, Inc. Presents at 15th Annual Needham Healthcare Conference, Apr-12-2016 10:00 AM. Venue: The Westin NY Grand Central Hotel, 212 East 42nd Street, New York, NY 10017, United States.

Aerpio Therapeutics, Inc. Announces Positive Results of AKB-9778 in Patients with Diabetic Retinopathy from TIME-2 Phase 2a Study

Aerpio Therapeutics, Inc. announced promising results in diabetic retinopathy from the company’s phase 2a study (TIME-2) of its lead candidate, AKB-9778, a first-in-class Tie2 activator. AKB-9778, dosed at 15 mg BID subcutaneously, alone and in combination with Lucentis® (ranibizumab injection dosed at 0.3 mg intravitreally), improved underlying retinopathy according to pre-specified analyses by 2 or more steps on the diabetic retinopathy severity scale (DRSS) in the study eye at month 3. Rates of 2-step improvement were 10.0%, and 11.4% in the AKB-9778 monotherapy and AKB-9778+Lucentis combination therapy arms, respectively, compared to 8.8% of patients receiving Lucentis® alone. Further, in the fellow eye, patients that were exposed to systemic AKB-9778 achieved a 2-step or greater DRSS improvement at 3 months in 11.4% of patients, versus 4.2% of patients receiving placebo. The clinical findings were presented by Pravin U. Dugel, M.D., at the Angiogenesis, Exudation, and Degeneration 2016 meeting, which took place in Miami, FL, on February 6, 2016.

Aerpio Therapeutics Inc. Appoints Steve Pakola as Chief Medical Officer

Aerpio Therapeutics Inc. has named a new chief medical officer. The company has named Dr. Steve Pakola to the newly created role. Pakola will lead the advancement of company's development pipeline and report to president and CEO Joseph Gardner, effective immediately. Pakola was most recently chief medical officer at Amakem. He was previously chief medical officer at ThromboGenics NV, where he was the lead inventor and developer of the company's main product. His other previous roles include senior-level clinical development positions at Boehringer Ingelheim Pharmaceuticals Inc., Quintiles and Organon Inc.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
March 31, 2016
--
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Aerpio Therapeutics, Inc., please visit www.aerpio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.